GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classement en actions
#3665
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Prix de l'action
$27.17
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$4.60B
Changement (1 jour)
-1.33%
Changement (1 an)
-13.30%
Pays
IN
Échange GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Catégorie
Healthcare
Revenus pour GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Revenus en Jun 2026 TTM : $436.46M
Selon les derniers rapports financiers de GlaxoSmithKline Pharmaceuticals Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $436.46M. En 2024, l'entreprise a réalisé un chiffre d'affaires de $414.20M une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $395.68M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour GlaxoSmithKline Pharmaceuticals Limited de 2004 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $436.46M | -0.43% |
| 2025 | $438.37M | 5.84% |
| 2024 | $414.20M | 4.68% |
| 2023 | $395.68M | -8.37% |
| 2022 | $431.83M | 8.05% |
| 2021 | $399.65M | -6.62% |
| 2020 | $428.01M | -4.99% |
| 2019 | $450.48M | 2.15% |
| 2018 | $441.02M | -1.67% |
| 2017 | $448.50M | 4.70% |
| 2016 | $428.36M | 1.31% |
| 2015 | $422.83M | -0.90% |
| 2013 | $426.68M | -11.70% |
| 2012 | $483.21M | 7.85% |
| 2011 | $448.05M | -6.91% |
| 2010 | $481.30M | 17.28% |
| 2009 | $410.39M | 17.56% |
| 2008 | $349.09M | -14.58% |
| 2007 | $408.65M | 14.51% |
| 2006 | $356.86M | 5.90% |
| 2005 | $336.97M | 3.85% |
| 2004 | $324.46M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $79.67B | 18,152.62% |
US
|
|
| $99.34B | 22,659.12% |
US
|
|
| $64.39B | 14,651.79% |
US
|
|
| $66.40B | 15,113.23% |
US
|
|
| $77.52B | 17,660.65% |
CH
|
